Considerations and guidance on discontinuation of upadatinib after one year of use

Upadacitinib, a highly effective JAK1 selective inhibitor, has been widely used in the treatment of chronic immune diseases such as rheumatoid arthritis, atopic dermatitis and ulcerative colitis. These diseases often have persistent or recurring characteristics. Therefore, the duration of medication and the decision to discontinue medication need to be carefully made based on the patient's specific condition and the doctor's assessment.

In most cases, upadatinib needs to be used long-term to ensure effective control of symptoms and stability of the condition. If the patient's condition improves significantly and remains stable for a long time after continuing to take upatinib for one year, the doctor may consider adjusting the treatment plan, including gradually reducing the drug dose or exploring the possibility of discontinuing the drug. However, whether the drug can be completely stopped depends on the degree of disease control, symptom relief, and potential risk of recurrence.

The risk of discontinuing medication is that it may lead to a recurrence or exacerbation of the condition, especially for immune system-related diseases such as rheumatoid arthritis and atopic dermatitis. Once the medication is stopped, the immune system may become active again, triggering inflammation and a return of symptoms. Therefore, before deciding to discontinue a medication, doctors will typically perform a thorough evaluation, including blood tests and monitoring of the condition, to ensure it is safe to gradually reduce the dose or discontinue the medication.

For some patients, even after taking upadatinib for one year, doctors may still recommend continuing the medication to maintain long-term disease control. In the treatment of chronic diseases, continued medication is key to preventing recurrence, further damage to joints, or worsening of skin symptoms. During the process of reducing or discontinuing medication, doctors will also closely monitor changes in the patient's condition to ensure that the condition remains stable despite reducing the dosage of medication.

Additionally, there are significant individual differences in how patients respond to medications. Some patients respond well to upadatinib and experience significant symptom relief, so the possibility of discontinuing the drug is relatively high; while other patients may require long-term medication to maintain the stability of their condition. Therefore, the decision to discontinue medication should be made under the strict guidance of a doctor, and patients should never decide to discontinue medication on their own.